Navigation Links
Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Date:12/21/2010

million patients to date.

Summary of Settlements

Takeda has granted Mylan, Watson, and Ranbaxy licenses to enter the U.S. market with generic ACTOS on August 17, 2012, subject to regulatory approval, or earlier under certain circumstances.

Mylan, Watson, and Ranbaxy are first-filers of ANDAs with paragraph IV certifications for ACTOS, and it is anticipated that the U.S. Food and Drug Administration will grant these companies 180-day marketing exclusivity. Takeda has granted Alphapharm, Sandoz, Aurobindo, Dr. Reddy, Wockhardt, the Synthon defendants, Teva, and Torrent licenses to enter the U.S. market with generic ACTOS beginning 180 days after the first-filers, subject to regulatory approval. Takeda has granted Teva a license to market an authorized generic version of ACTOS in the U.S. beginning on August 17, 2012, or earlier under certain circumstances.

Takeda also has granted Mylan a license to market generic ACTOplus met in the U.S. on December 14, 2012, or earlier under certain circumstances, subject to regulatory approval. As a first-filer of a patent certification for this product, it is anticipated that Mylan will receive 180 days of marketing exclusivity. Sandoz, Ranbaxy, Torrent, Watson, Aurobindo, Wockhardt, and Teva have been granted licenses to enter the U.S. market with generic ACTOplus met beginning 180 days after the first-filer, or earlier under certain circumstances, subject to regulatory approval. Takeda has granted Teva a license to market an authorized generic version of ACTOplus met in the U.S. beginning on December 14, 2012, or earlier under certain circumstances.

Lastly, Takeda has granted Sandoz a license to enter the U.S. market with generic duetact on December 14, 2012, or earlier under certain circumstances.

About ACTOS® (pioglitazone HCl) Family of Products Indications and Usage

ACTOS® (pioglitazone HCl), ACTOplus met® (p
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Victoria Vein & Surgery Clinic is the only clinic offering ... Victoria, Texas . The clinic specializes in ... treatments for a variety of medical and cosmetic conditions. High-end ... services for their patients. Since adding laser tattoo removal, Victoria ... residents get rid of their unwanted ink. ...
(Date:3/27/2015)... YORK , March 27, 2015 A new ... Latin America – Chile ... are top targets for IVD firms.  The healthcare ... figures heavily into IVD strategies for the Latin American continent ... to support globally distributed supply operations. However, the country,s regional ...
(Date:3/27/2015)... CAMBRIDGE, Mass. , March 27, 2015 /PRNewswire/ ... unique platform for drug discovery and development services ... assays for the pharmaceutical industry, announced financial results ... Timothy C.  Tyson, Chairman of XRpro ... steps to successfully transition from development stage to ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to... -- DALLAS, September 6, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... The editors of Inc. Magazine have included Qosina Corporation, ... 5000" List , which acknowledges the top 5,000 fastest ... being recognized for the second consecutive year on the ... the "Inc. 500" in 1989 and "Inc. 5000" in ...
Cached Medicine Technology:Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 2Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 3Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 4Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 5Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 6Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 7Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 8Qosina Recognized for Second Consecutive Year on the 'Inc. 5000' List 2
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
(Date:3/28/2015)... OR (PRWEB) March 28, 2015 Lately ... the media regarding recent changes and proposals around the ... , current and former collegiate student-athletes across a spectrum ... and reflect on common challenges. The special panel consists ... country in sports ranging from football, track and field, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 ARDX will sponsor ... from 12pm -3pm at the Chesapeake Conference Center in Chesapeake, ... sponsoring an empowering event for women in the Hampton Roads ... the Stories of Women’s Lives. Women grow stronger through ... each other. This year the WWC™ theme is T-talk ...
(Date:3/27/2015)... Long Island, NY (PRWEB) March 27, 2015 ... objective, cancer-focused training and business criteria for the spa ... and services to clients who have experienced or are ... of the global Spafinder Wellness 365® Network, will be ... Spafinder.com and recognized as a provider of safe, therapeutic ...
(Date:3/27/2015)... Mo (PRWEB) March 27, 2015 ... for patients undergoing percutaneous coronary intervention (PCI), resulting ... have observed a “risk-treatment paradox,” in which the ... from treatment are treated less often with bleeding ... at Saint Luke’s Mid America Heart Institute asked ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... ... don,t need the pretty bottles or sweet aroma of fragrant lotions and cleansers-men ... tailored specifically to a man,s needs without added synthetic ingredients that may be ... uses the purity of nature to enhance the skin,s surface and makes a ...
... ... Drive in Beverly Hills to Main Street in small towns across America. The medical community ... growing epidemic. , ... PA (PRWEB) June 1, 2010 -- Nearly 7 million Americans are abusing prescription drugs – ...
... ... Harmful Bacteria, Including MRSA. Jan-Pro, Global Leader in Commercial Cleaning, Once Again Leads the ... Offer Powerful New Solution in the control of infectious microorganisms - EnviroShield Disinfectant Technology ... (PRWEB) June ...
... ... of a novel combination of two FDA Approved topical medications. This triple blind controlled ... ... Oscar Klein M.D. today announced the results of a triple blind hair loss research study ...
... ... a brand new buy back plan. , ... (PRWEB) – CosmeticLaserWorld.com ( www.cosmeticlaserworld.com ), a market leader in ... should purchase equipment from the reseller. Under an Investment Protection Plan, the company will ...
... - Shionogi Pharma, Inc., a U.S.-based group company of ... results of two pivotal studies of the investigational new ... for the treatment of primary premature ejaculation (PE). These ... (AUA) Annual Meeting in San Francisco. Evaluating a ...
Cached Medicine News:Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 2Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 3Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 4Health News:Medical Community Responds to Prescription Drug Abuse 2Health News:Medical Community Responds to Prescription Drug Abuse 3Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 2Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 3Health News:Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness 2Health News:Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness 3Health News:CosmeticLaserWorld.com Gives Buyers Peace of Mind Through Industry-Leading Investment Protection Plan 2Health News:Pivotal data for the investigational treatment PSD502 for primary premature ejaculation 2Health News:Pivotal data for the investigational treatment PSD502 for primary premature ejaculation 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: